X4 Pharmaceuticals, Inc. (XFOR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1163012,
    "name": "X4 Pharmaceuticals, Inc.",
    "stock_name": "X4 Pharmaceuticals, Inc.",
    "full_name": "X4 Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/x4-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "3.80",
    "chg": 0.6,
    "chgp": "18.94%",
    "dir": 1,
    "prev_price": "3.19",
    "mcapval": "76.10",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US98420X1037",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.31 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/x4-pharmaceuticals-inc-1163012-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is X4 Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-x4-pharmaceuticals-inc-technically-bullish-or-bearish-3548004",
        "imagepath": "",
        "date": "2025-09-20 20:07:43",
        "description": "As of 29 August 2025, the technical trend for X4 Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the RSI is bearish for both weekly and monthly periods. Moving averages are showing a mildly bearish trend on the daily timeframe. Overall, the indicators suggest a mixed outlook, with the weekly Bollinger Bands and KST being mildly bullish, while the monthly Bollinger Bands and KST are bearish. \n\nIn terms of performance, X4 Pharmaceuticals has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date return of -85.28% versus the S&P 500's 12.22%. This stark contrast highlights the current bearish sentiment surrounding the stock...."
      },
      {
        "title": "Is X4 Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-x4-pharmaceuticals-inc-overvalued-or-undervalued-3544189",
        "imagepath": "",
        "date": "2025-09-20 18:40:07",
        "description": "As of 8 August 2025, the valuation grade for X4 Pharmaceuticals, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued, particularly given its troubling financial metrics, including a Price to Book Value of 1.08, an EV to Sales ratio of 0.47, and an alarming ROCE of -878.57%. \n\nIn comparison to its peers, X4 Pharmaceuticals shows a less favorable position, with Foghorn Therapeutics, Inc. having a more negative EV to EBITDA of -1.4807 and Invivyd, Inc. at -1.7450. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -85.28% compared to the index's 12.22%, reinforcing the perception of overvaluation amidst its financial struggles...."
      }
    ],
    "total": 7,
    "sid": "1163012",
    "stock_news_url": "https://www.marketsmojo.com/news/x4-pharmaceuticals-inc-1163012"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is X4 Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 20:07:43

As of 29 August 2025, the technical trend for X4 Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the RSI is bearish for both weekly and monthly periods. Moving averages are showing a mildly bearish trend on the daily timeframe. Overall, the indicators suggest a mixed outlook, with the weekly Bollinger Bands and KST being mildly bullish, while the monthly Bollinger Bands and KST are bearish. In terms of performance, X4 Pharmaceuticals has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date return of -85.28% versus the S&P 500's 12.22%. This stark contrast highlights the current bearish sentiment surrounding the stock....

Is X4 Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:40:07

As of 8 August 2025, the valuation grade for X4 Pharmaceuticals, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued, particularly given its troubling financial metrics, including a Price to Book Value of 1.08, an EV to Sales ratio of 0.47, and an alarming ROCE of -878.57%. In comparison to its peers, X4 Pharmaceuticals shows a less favorable position, with Foghorn Therapeutics, Inc. having a more negative EV to EBITDA of -1.4807 and Invivyd, Inc. at -1.7450. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -85.28% compared to the index's 12.22%, reinforcing the perception of overvaluation amidst its financial struggles....

View All News